
STATUS UPDATE:

- (A) PROCEEDINGS RELATED TO FACILITY AGREEMENTS ENTERED INTO WITH THE CREST ENTITIES**
 - (B) ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN KAO KUN**
 - (C) UPDATES ON VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA**
 - (D) UPDATES TO SHAREHOLDERS ON OTHER CLAIM(S) AGAINST OUE LIPPO HEALTHCARE LIMITED**
-

1. INTRODUCTION

- 1.1. Unless otherwise defined, capitalised terms herein shall have the same meaning as ascribed to them in the following announcements ("**Previous Announcements**"):
- (a) the announcements of OUE Lippo Healthcare Limited (the "**Company**") between 3 May 2016 to 30 March 2021, in relation to, *inter alia*, the appointment of receivers (the "**Receivers**") over certain subsidiaries of the Company¹. For the avoidance of doubt, the Receivers have been discharged over all three subsidiaries on 18 August 2020;
 - (b) the announcements of the Company between 13 December 2017 to 16 March 2021 in relation to the arbitration and enforcement proceedings against David Lin Kao Kun ("**David Lin**")²; and
 - (c) the announcements of the Company between 22 February 2017 to 22 March 2021 in relation to on-going litigation with Weixin Hospital Investment Management (Shanghai) Co. Ltd (卫心医院投资管理(上海)有限公司) ("**Weixin**")³.

¹ Please refer to the Company's announcements dated 3 May 2016, 6 May 2016, 8 July 2016, 8 August 2016, 15 August 2016, 16 September 2016, 13 October 2016, 21 October 2016, 14 November 2016, 24 November 2016, 15 December 2016, 13 January 2017, 11 March 2017, 29 April 2017, 17 May 2017, 16 June 2017, 29 June 2017, 13 July 2017, 22 August 2017, 28 September 2017, 25 October 2017, 22 November 2017, 28 December 2017, 24 January 2018, 28 February 2018, 27 March 2018, 30 April 2018, 28 May 2018, 26 June 2018, 2 July 2018, 26 July 2018, 27 August 2018, 27 September 2018, 29 October 2018, 30 November 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019, 31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 15 September 2019, 30 September 2019, 30 October 2019, 29 November 2019, 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, 29 April 2020, 19 May 2020, 29 May 2020, 30 June 2020, 9 July 2020, 16 July 2020, 24 July 2020, 30 July 2020, 12 August 2020, 20 August 2020, 31 August 2020, 25 September 2020, 29 September 2020, 15 October 2020, 29 October 2020, 30 November 2020, 31 December 2020, 8 January 2021, 29 January 2021, 26 February 2021 and 30 March 2021.

² Please refer to the Company's announcements dated 13 December 2017, 11 January 2018, 17 January 2019, 29 January 2019, 28 February 2019, 28 March 2019, 12 April 2019, 29 April 2019, 31 May 2019, 26 June 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 30 October 2019, 3 November 2019, 29 November 2019, 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, 22 April 2020, 29 April 2020, 29 May 2020, 30 June 2020, 30 July 2020, 27 August 2020, 31 August 2020, 29 September 2020, 29 October 2020, 30 November 2020, 31 December 2020, 29 January 2021, 26 February 2021 and 16 March 2021.

³ Please refer to the Company's announcements dated 22 February 2017, 20 December 2017, 6 August 2018, 23 August 2018, 30 November 2018, 5 December 2018, 27 December 2018, 29 January 2019, 28 February 2019, 28 March 2019, 29 April 2019,

2. PROCEEDINGS RELATED TO FACILITY AGREEMENTS ENTERED INTO WITH THE CREST ENTITIES

There are no material updates on the proceedings with the Crest Entities.

3. ARBITRATION AND ENFORCEMENT PROCEEDINGS AGAINST DAVID LIN

The Company refers to the Previous Announcements, in particular, the announcements dated 31 January 2020, 29 April 2020, 29 May 2020, 30 November 2020 and 31 December 2020 in relation to the recognition and final enforcement proceedings in Taiwan in respect of the Arbitration Award against David Lin.

On or around 12 March 2021, the Company has received a sum of SGD710,913.50 (excluding deduction of bank charges), being the equivalent of NTD14,991,033 in relation to the deposit and trust assets held by David Lin in the bank accounts with Standard Chartered Bank.

4. VARIOUS LITIGATION PROCEEDINGS IN THE PEOPLE'S REPUBLIC OF CHINA

4.1 Proceedings commenced by Wuxi Yilin Health Management Co. Ltd (无锡医霖健康管理公司) ("Wuxi Yilin Health")

The Company refers to its Previous Announcements, including the announcements dated 5 December 2018, 29 January 2019, 14 October 2019 and 30 October 2019 in relation to the proceedings commenced by Wuxi Yilin Health, a subsidiary of the Company, against David Lin before the Wuxi Intermediate Court. In these proceedings, Wuxi Yilin Health contends that David Lin breached his fiduciary duties to Wuxi Yilin Health, by causing Wuxi Yilin Health to enter into a commitment letter dated 28 July 2014, wherein it agreed, *inter alia*, that 1) the capital injection of Wuxi Yilin Health would not entail any shareholding interest in Wuxi New District Phoenix Hospital Co. Ltd. ("Wuxi Co."); and 2) Wuxi Yilin Health would not object if Shanghai Yilin Management Consulting Co. Ltd transfers the shares of Wuxi Co. to a third party.

On 14 October 2019, the Company was informed by its PRC counsel that the Wuxi Intermediate Court has dismissed Wuxi Yilin Health's claim against David Lin.

On 16 October 2019, Wuxi Yilin Health filed an appeal to the Jiangsu Higher Court against the Wuxi Intermediate Court's decision.

The Court has fixed a hearing for the appeal on 12 April 2021.

5. UPDATES TO SHAREHOLDERS ON OTHER CLAIM(S) AGAINST OUE LIPPO HEALTHCARE LIMITED

There are no material updates on the other claims against the Company.

31 May 2019, 28 June 2019, 30 July 2019, 30 August 2019, 30 September 2019, 14 October 2019, 30 October 2019, 25 November 2019, 29 November 2019, 12 December 2019 and 30 December 2019, 31 January 2020, 28 February 2020, 30 March 2020, 29 May 2020, 30 June 2020, 30 July 2020, 31 August 2020; 29 September 2020, 29 October 2020, 30 November 2020, 31 December 2020, 29 January 2021, 26 February 2021 and 22 March 2021.

The Company will provide further updates on the status of the above matters through SGXNET in accordance with the requirements under the applicable Catalist Rules.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
31 March 2021

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "Exchange") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Ms. Gillian Goh, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.